Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) filed an amended registration statement (S-1/A) covering 5,500,000 shares of common stock, a figure that towers over the company's post-reverse-split float of roughly 461,000 shares. The filing is tied to a primary offering aimed at regaining Nasdaq listing compliance.
Reverse Split Reshapes the Cap Table
A 1-for-11 reverse stock split became effective May 29, 2026, collapsing the outstanding share count and resetting the per-share price. On a post-split basis, Eloxx's common-stock base sits at approximately 461,000 shares — a figure that makes the proportional weight of any new issuance exceptionally large.
Pre-Funded Warrants Are the Core Dilution Vector
The filing's most structurally significant feature is the pre-funded warrant overhang. Eloxx currently has 4,958,919 pre-funded warrants outstanding at an exercise price of $0.11 per share. The offering adds another 2,770,000 pre-funded warrants exercisable at $0.01 per share. Combined, these 7,728,919 warrants represent more than 16 times the current outstanding common share count.
Pre-funded warrants carry no expiration date and require only a nominal exercise price, which means they function almost identically to issued shares from a dilution standpoint. The $0.01 exercise price on the newly offered tranche is effectively cashless relative to any realistic trading price, making conversion a near-certainty once holders choose to exercise.
Fixed-Price Structure — No Variable-Rate Conversion
Notably, the offering does not include variable-rate convertible notes, equity lines with floating discounts, or other instruments typically associated with so-called toxic financing structures. The securities are priced at fixed terms, which means the dilution calculus is deterministic: investors can model the fully diluted share count without accounting for price-dependent conversion ratios.
Compliance and Filing Status
Eloxx is currently delinquent on its periodic SEC filings and has disclosed an identified material weakness in internal controls. The offering is part of a broader effort to meet Nasdaq's continued-listing requirements. Until the company regains compliance, trading-venue risk remains a structural consideration embedded in the capital stack.
Dilution Math in Context
If every pre-funded warrant — existing and newly offered — were exercised, the fully diluted common share count would rise from approximately 461,000 to roughly 8.19 million shares, an increase of roughly 1,576%. The aggregate exercise proceeds to the company from the new $0.01 warrants would total just $27,700, underscoring that the capital raised through this tranche is negligible relative to the equity given up. The existing $0.11 warrants would bring in approximately $545,000 upon full exercise.
The registration of 5,500,000 shares under this S-1/A covers a substantial portion — but not all — of the combined warrant overhang, meaning additional registrations could follow as remaining warrants become eligible for resale.